2 Million Children Must Be Jabbed to Prevent 1 ICU Admission

Via Mercola

Story at-a-glance

  • A cost-benefit analysis shows the COVID jab increases children’s risk of dying from COVID infection. Children under 18 are also 51 times more likely to die from the jab than they are to die from COVID infection if not vaccinated
  • Four million doses must be administered to children, 5 to 11 years of age, to prevent a single ICU admission in this age group. Assuming two doses per child, that means 2 million children must risk potentially serious side effects to prevent a single child from requiring intensive care due to COVID-19
  • The Israeli Ministry of Health recently surveyed people who had received a third booster to determine the actual rate of side effects. Of the 2,068 interviewed individuals, 0.3% required hospitalization for an adverse event; three times more women than men (6.9% versus 2.1%) experienced neurological problems; 9.6% of women under the age of 54 experienced menstrual irregularities; 26.4% of those with preexisting anxiety disorder or depression experienced a worsening of their symptoms, as did 24.2% of those with preexisting autoimmune disorders
  • German health insurance data also show an alarming trend. After analyzing the medical data of 10.9 million insured individuals, one large health insurance company concluded that 400,000 doctors’ visits could be realistically attributed to jab side effects. Extrapolated to the total population of Germany, the total number of jab side effects requiring medical care would be 3 million, about 1,000% higher than admitted by the German Ministry of Health
  • Two autopsies of teenage boys who died within days of their COVID jabs revealed the shot caused their deaths

Continue reading “2 Million Children Must Be Jabbed to Prevent 1 ICU Admission”

The News that Doesn’t make it to “Mainstream”

Guest Post by Dr. Robert Malone

Please watch this video.
It is ten minutes long, and may be the best time you spend today.
This is what we are up against.


Covid-19 vaccines and treatments: we must have raw data, now BMJ 2022 (Published 19 January 2022)

We are left with publications but no access to the underlying data on reasonable request. This is worrying for trial participants, researchers, clinicians, journal editors, policy makers, and the public. The journals that have published these primary studies may argue that they faced an awkward dilemma, caught between making the summary findings available quickly and upholding the best ethical values that support timely access to underlying data. In our view, there is no dilemma; the anonymised individual participant data from clinical trials must be made available for independent scrutiny.

Pharmaceutical companies are reaping vast profits without adequate independent scrutiny of their scientific claims. The purpose of regulators is not to dance to the tune of rich global corporations and enrich them further; it is to protect the health of their populations. We need complete data transparency for all studies, we need it in the public interest, and we need it now.

A huge thank you to BMJ (British Medical Journal), who again has shown the bravery and honesty to tell truth to power.

Continue reading “The News that Doesn’t make it to “Mainstream””